The air sacs of the lungs, called alveoli, depend on a surprisingly diverse cast of cells to keep you breathing. Two epithelial cell types get most of the attention: type I cells, which form the vast, paper-thin surface where oxygen and carbon dioxide swap between air and blood, and type II cells, which produce the slippery coating called surfactant that keeps those air sacs from collapsing. But the alveolar neighborhood also includes specialized capillary cells, resident immune cells, and supporting fibroblasts, each with a distinct job. Understanding what each cell type does, and how they cooperate, clarifies why lung diseases from pneumonia to pulmonary fibrosis can be so devastating when that cooperation breaks down.
Type I Cells and the Gas Exchange Surface
Type I alveolar epithelial cells (often abbreviated AT1) are the workhorses of gas exchange. They stretch into extraordinarily thin, flat sheets, sometimes just a few tenths of a micrometer thick, forming most of the surface area where oxygen passes into the blood and carbon dioxide passes out. In a human lung, that combined surface area exceeds 100 square meters, roughly the size of a singles tennis court packed into your chest.1Oxford Academic (American Journal of Respiratory and Critical Care Medicine). On the Tricks Alveolar Epithelial Cells Play to Make a Good Lung Despite covering about 95 percent of the alveolar lining, type I cells are actually outnumbered by type II cells. They achieve their enormous coverage because each individual cell spreads out so widely.
This extreme thinness is not just an architectural quirk. Gas molecules move by diffusion, and diffusion is faster over shorter distances. The air-blood barrier, made up of the type I cell, a thin basement membrane, and the capillary wall, needs to be as slim as possible to allow rapid gas exchange during the fraction of a second that blood spends passing through an alveolar capillary. Type I cells sit in close anatomic contact with a specific capillary cell type called the aerocyte, reinforcing the idea that the barrier is built as a matched pair optimized for gas transfer.2American Journal of Respiratory Cell and Molecular Biology. Capillary Endothelial Cell Subtypes in the Lung: Markers and Response to Developmental Lung Injury
A useful way to think about type I cells: they sacrifice almost everything, metabolic complexity, the ability to divide, thick protective walls, in order to be as transparent as possible to gas molecules. That makes them efficient, but also fragile. When type I cells are damaged by infection or toxins, the lung’s ability to move oxygen plummets almost immediately.
Type II Cells and Surfactant Production
Type II alveolar epithelial cells (AT2) are smaller, cube-shaped, and packed with the cellular machinery needed to manufacture pulmonary surfactant.3PubMed. Biology of alveolar type II cells Surfactant is a mixture of lipids and proteins that coats the inner surface of each alveolus, and its primary job is to lower surface tension.4PubMed. Regulation of surfactant secretion in alveolar type II cells Without it, the watery film lining the alveoli would generate enough surface tension to collapse the air sacs on every exhale, making breathing impossible.
The surfactant film does two things especially well. It forms rapidly at the air-liquid interface, and when the alveolar surface area shrinks during exhalation, the compressed film drives surface tension down to extremely low values.5PubMed Central. The biophysical function of pulmonary surfactant The key ingredients are specific phospholipids, particularly phosphatidylcholine and phosphatidylglycerol, which contribute to the tension-lowering properties.6PubMed. The role of lipids in pulmonary surfactant Babies born very prematurely often lack adequate surfactant, which is why neonatal respiratory distress syndrome was historically so dangerous before synthetic surfactant replacement became available.
Beyond surfactant, type II cells serve a second critical role: they act as the lung’s resident stem cells. When type I cells are damaged, type II cells can divide and then transform into new type I cells to patch the barrier.7PubMed Central. Wnt signaling regulates trans-differentiation of stem cell like type 2 alveolar epithelial cells to type 1 epithelial cells This regenerative capacity makes type II cells central to both day-to-day maintenance of the alveolar lining and recovery after acute injury.8PubMed Central. Unlocking Alveolar Regeneration: AT2 Stem Cells, Signaling Networks, and Therapeutic Frontiers
How Breathing Itself Regulates Type II Cells
One of the more surprising findings about type II cells is that the physical act of breathing directly controls their behavior. As lungs inflate and deflate, alveolar walls stretch and relax. That mechanical stretch is now considered the main physiological trigger for surfactant release.9Comparative Biochemistry and Physiology Part A: Molecular & Integrative Physiology. Stretch stimulation: its effects on alveolar type II cell function in the lung In other words, the deeper you breathe, the more surfactant gets pushed out to coat the expanding surface.
Stretch also influences type II cell fate in broader ways. Cyclic stretching promotes the differentiation of fetal type II cells during development, increasing the expression of key surfactant proteins and boosting the secretion of lipid components that make surfactant functional.10PubMed. Mechanical stretch promotes alveolar epithelial type II cell differentiation Stretch can also trigger type II cells to convert into type I cells or, at extreme levels, to undergo programmed cell death. This last point matters clinically: mechanical ventilation in intensive care units can overstretch alveoli, potentially harming the very cells needed for lung repair.
Keeping Alveoli Dry From the Inside
Efficient gas exchange requires alveoli to be kept nearly dry. A thin layer of fluid is normal and necessary, but excess fluid, pulmonary edema, drowns the air-blood barrier and blocks oxygen transfer. Both type I and type II epithelial cells actively pump sodium ions from the air side of the alveolus toward the blood side, creating an osmotic gradient that pulls water along with the sodium.11PubMed Central. Bench-to-bedside review: the role of the alveolar epithelium in the resolution of pulmonary edema in acute lung injury The sodium pump on the basal surface of these cells is the engine behind this process, and channels on the air-facing surface let sodium flow in to be transported.12Frontiers in Physiology. Why Do We have to Move Fluid to be Able to Breathe?
When the epithelial barrier is breached, for example during acute respiratory distress syndrome (ARDS), this fluid-clearing machinery breaks down. Protein-rich fluid floods the alveoli, and the remaining epithelial cells struggle to pump it out fast enough.13PubMed. Alveolar epithelial fluid transport in acute lung injury: new insights That flooding is a major reason why ARDS patients need mechanical ventilation and why blood oxygen levels can drop so dramatically.
The Capillary Side of the Barrier
For decades, the tiny blood vessels woven around each alveolus were treated as a uniform mesh. Recent work has overturned that assumption. Alveolar capillaries are actually mosaics of two intermingled endothelial cell types with distinct shapes and jobs. One type, called the aerocyte, is specialized for gas exchange and for letting white blood cells cross from blood into the lung. Aerocytes are unique to the lung and have no equivalent elsewhere in the body. The other type, called gCap (for “general” capillary), regulates blood vessel tone and acts as a stem cell that can replace damaged capillary cells.14Nature. Capillary cell-type specialization in the alveolus
The aerocyte-gCap pairing on the blood side mirrors the type I-type II pairing on the air side: one cell type optimized for the core physical job, the other serving as the regenerative backup. These capillary cells interlock in complex patterns the researchers who discovered them described as “Swiss-cheese-like,” with each type threading through gaps in the other.
Immune Sentinels in the Alveoli
Sitting on the inner surface of each alveolus, among the epithelial cells and surfactant film, are alveolar macrophages. These immune cells are the first line of defense against inhaled bacteria, viruses, and debris. They engulf and destroy pathogens, clear dead cells, and even help recycle surplus surfactant.15PubMed. Gm-CSF regulates pulmonary surfactant homeostasis and alveolar macrophage-mediated innate host defense
The lung also hosts a second, less well-known macrophage population buried in the tissue between alveoli: interstitial macrophages. These cells are physically smaller and play a different role. While alveolar macrophages are better at phagocytosis, killing microbes, and generating reactive oxygen species, interstitial macrophages are more effective at releasing signaling molecules that coordinate a targeted immune response and at presenting foreign material to other immune cells.16The Journal of Immunology. Characterization of murine lung interstitial macrophages in comparison with alveolar macrophages in vitro In human tissue, this size difference is dramatic: alveolar macrophages average about 16 micrometers across, while interstitial macrophages average about 8 micrometers.17Experimental and Molecular Pathology. Functional and Morphological Differences between Human Alveolar and Interstitial Macrophages The two populations essentially divide labor: one fights invaders on the front line, and the other helps orchestrate the broader immune response from behind.
The Support Crew Between Alveoli
Wedged in the thin walls between adjacent alveoli are fibroblasts, the cells that build and maintain the structural scaffolding of the lung. These are not bystanders. Different fibroblast subtypes direct the behavior of the epithelial stem cell niche during development, repair, and day-to-day homeostasis. Matrix fibroblasts lay down the extracellular framework, myofibroblasts provide tensile strength, and lipofibroblasts support the differentiation of nearby epithelial cells.18PubMed Central. Resident interstitial lung fibroblasts and their role in alveolar stem cell niche development, homeostasis, injury, and regeneration
Lipofibroblasts are particularly interesting because they sit right next to type II cells and supply growth signals that help maintain those cells’ stem-like properties. Recent work in mice identified a surface marker (integrin α8) that reliably labels lipofibroblasts and showed that these cells produce signaling factors known to support type II cells.19PubMed Central. Integrin α8 is a useful cell surface marker of alveolar lipofibroblasts When the fibroblast population is disrupted, type II cells lose their regenerative edge, which helps explain why scarring diseases like pulmonary fibrosis are so hard to reverse: the support crew is damaged alongside the cells they are supposed to nurture.
What Happens When Alveolar Cells Fail
ARDS illustrates what goes wrong when alveolar epithelial cells are overwhelmed. Inflammation-driven damage to the epithelial and capillary barriers leads to a cascade of problems: fluid floods into the air spaces, surfactant breaks down, and the remaining cells cannot clear the edema fast enough.20PubMed Central. Pathophysiology of Acute Respiratory Distress Syndrome and COVID-19 Lung Injury The dysfunction of alveolar epithelial cells is now recognized as a central driver of ARDS, not just a downstream consequence of inflammation.21PubMed Central. Alveolar Epithelial Cell Dysfunction in Acute Respiratory Distress Syndrome: Mechanistic Insights and Targeted Interventions
In chronic diseases, the damage accumulates more slowly but is no less consequential. In idiopathic pulmonary fibrosis (IPF), type II cells show signs of premature aging, or senescence. Senescent type II cells lose their ability to self-renew and replenish the type I cells that form the gas-exchange surface.22American Journal of Respiratory and Critical Care Medicine. Senescence of Alveolar Type 2 Cells Drives Progressive Pulmonary Fibrosis Researchers have confirmed that type II cells from IPF lungs stain positive for markers of senescence, while type II cells from healthy lungs do not.23PLOS ONE. miR-34 miRNAs Regulate Cellular Senescence in Type II Alveolar Epithelial Cells of Patients with Idiopathic Pulmonary Fibrosis Once the stem cell population stalls, the lung cannot rebuild its barrier, and scar tissue fills the gaps instead.
The Aging Alveolar Niche
Even without a specific disease, aging takes a toll on the alveolar cell community. Type II cells from older lungs show increased inflammatory signaling, impaired surfactant metabolism, and reduced ability to proliferate after injury.24PubMed. Aging impairs alveolar epithelial type II cell function in acute lung injury But it is not just the epithelial cells that change. Transcriptomic analysis of aged human lungs reveals a decline across the entire stem cell niche: the mesenchymal support cells produce less collagen and elastin, and macrophages show disrupted genetic programs and impaired communication with type II cells.25PubMed Central. Transcriptomics Analysis Identifies the Decline in the Alveolar Type II Stem Cell Niche in Aged Human Lungs
This niche-wide deterioration helps explain why older adults are disproportionately vulnerable to pneumonia, ARDS, and other lung injuries. The repair machinery is not just slower; the entire support system that tells stem cells where to go and what to become has degraded.26PubMed Central. Alveolar epithelial regeneration in the aging lung It reframes age-related lung vulnerability as a problem of cellular teamwork, not merely cellular wear.
COVID-19 and Alveolar Cell Vulnerability
The pandemic brought intense scrutiny to which alveolar cells SARS-CoV-2 targets. The virus enters cells through a receptor called ACE2. Lab-grown type II cells derived from human stem cells showed that roughly 15 percent of these cells express ACE2 on their surface, making them susceptible to infection.27Cell. Human iPSC-Derived Alveolar Epithelial Type 2 Cells Implicated in Infectious Disease Pathogenesis of SARS-CoV-2 In actual COVID-19 lung tissue, however, the picture was more complicated. ACE2 was selectively upregulated on pulmonary endothelial cells in patients with ARDS, while type II cells did not show significant ACE2 upregulation. Patients who died from COVID-19-related ARDS had notable loss of type II cells overall.28PubMed Central. Increased Angiotensin-Converting Enzyme 2 and Loss of Alveolar Type II Cells in COVID-19–related Acute Respiratory Distress Syndrome
The loss of type II cells in severe COVID-19 is a double blow. It removes both the surfactant factory and the stem cell reservoir the lung needs for repair. This is part of why severe COVID pneumonia could take weeks or months to resolve: the regenerative cells were among the casualties.
When Surfactant Production Begins
Type II cells do not switch on all at once during fetal development. In human fetuses, surfactant-producing type II cells are undetectable around weeks 22 to 25 of gestation. They become identifiable from about week 26, and their numbers increase substantially after week 28. By week 34, surfactant has spread throughout the alveoli.29Folia Morphologica. Unveiling surfactant protein-A dynamics in human fetal lung development: histological and immunohistochemical insights from Myanmar This developmental timeline is the biological reason behind the well-known clinical threshold of viability: babies born before about 24 to 26 weeks face extreme respiratory challenges in part because their lungs have not yet begun producing surfactant in meaningful quantities.
A Mammalian Innovation
Lungs are ancient organs, present in various forms across vertebrates from lungfish to birds. But alveolar type I cells appear to be a mammal-specific innovation. A comparative genomic study across vertebrate species identified AT1 cells as unique to mammals, along with several genes highly expressed in mammalian lungs that have no counterpart in other vertebrate groups. When one of these genes was deleted in mice, the animals developed severe respiratory defects, confirming its importance to the way mammalian lungs work.30PubMed. Origin and stepwise evolution of vertebrate lungs The implication is that the extreme thinness and enormous surface area of the mammalian gas-exchange barrier required the evolution of a dedicated cell type, one that other air-breathing vertebrates manage without, likely because their metabolic demands and body temperatures are different.
Why Drug Delivery to Alveoli Is Harder Than It Sounds
The alveolar surface seems like an ideal target for inhaled medications: it is enormous, well-perfused, and thin enough for molecules to cross into the bloodstream. But the surfactant layer that keeps alveoli from collapsing also acts as a gatekeeper. Experiments with nanoparticles showed that surfactant reduces particle uptake by alveolar epithelial cells by up to a hundredfold, regardless of the culture method used.31Scientific Reports. Pulmonary surfactant inhibition of nanoparticle uptake by alveolar epithelial cells For drug designers trying to deliver therapies through the lungs, whether for local treatment of lung disease or for systemic delivery into the blood, the surfactant barrier is a major obstacle. Particles that work beautifully in a dish full of cells fail when surfactant is present, because the coating traps or deflects them before they reach the cell surface. Formulation strategies increasingly have to account for surfactant interactions, not just particle size and chemistry, to have any chance of reaching their target.